Evidence map›Paper›PMID 41536193›Full record

ArticleDrug development research2026

Exploring CPP Enhanced Hypoxia Targeting: An Approach Using Radiolabeled 2-nitroimidazole TAT Conjugate.

Sweety Mittal, Akanksha Jain, Ashwini Babu, Chandan Kumar, Madhava B Mallia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug development research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sweety MittalRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Akanksha JainRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Ashwini BabuSchool of Chemical Sciences, UM-DAE Centre for Excellence in Basic Sciences, Mumbai, Maharashtra, India.
Chandan KumarRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Madhava B MalliaRadiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.ORCID 0000-0001-6487-3802

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mediated by their protein transduction domain, cell-penetrating peptides (CPPs) have been widely explored for facilitating intracellular delivery of drugs and small molecules. In this study, a radiolabeled, 2-nitroimidazole conjugated TAT (TAT - transactivator of transcription) peptide was prepared and evaluated for targeting tumor hypoxia. The conjugate was radiolabeled with iodine-125 and comprehensive in vitro and in vivo evaluations were conducted to assess its potential to target hypoxic cells. A radiolabeled [

Indexed as

Cell-Penetrating PeptidesGene Products, tatNitroimidazolestat Gene Products, Human Immunodeficiency VirusTumor HypoxiaAnimalsCell HypoxiaCell Line, TumorCHO CellsCricetinaeCricetulusHumansIodine RadioisotopesMiceTissue DistributionCell-Penetrating PeptidesGene Products, tatIodine-125Iodine RadioisotopesNitroimidazolestat Gene Products, Human Immunodeficiency VirusAuger electronscell penetrating peptidesHypoxiaIodine‐125NitroimidazoleTAT peptidesTransactivator of transcription

Identifiers

PMID41536193
PMCPMC12805414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.